Spark Therapeutics to Participate in Multiple Conferences in January
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Spark Therapeutics (ONCE) PT Lowered to $55 at Goldman Sachs Following US Pricing of Luxturna
January 4, 2018 8:04 AM ESTGoldman Sachs lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $55.00 (from $58.00) while maintaining a Neutral rating following the company's announcement that US pricing of lead gene therapy Luxturna is at $425K/eye (gross), below GSe of $500K/eye.
Goldman Sachs now... More
